CClinicalTrials.gg
CompletedNCT03448159FLOWUpdated Nov 4, 2022

Fluoxetine Opens Window to Improve Motor Recovery After Stroke

A Phase 2 interventional study of Fluoxetine Hydrochloride and Placebo in Stroke, Cerebrovascular Accident and Cerebral Infarction, sponsored by University Health Network, Toronto. Completed at 8 sites in Canada. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2022-11-04.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Study summary

The FLOW trial is a randomized placebo-controlled trial analyzing the effect of coupling an anti-depressant, fluoxetine (Prozac), and exercise to improve motor recovery following a stroke.

Read the detailed description

FLOW Trial is a randomized, placebo-controlled, blinded phase II trial evaluating the efficacy of coupling antidepressant therapy (e.g., selective serotonin reuptake inhibitor - fluoxetine) with exercise rehabilitation across multiple Canadian sites in 176 stroke patients. 88 patients will be enrolled in each arm of the study. Both groups will receive an exercise program in addition to standard of care rehabilitation, but only one group (the intervention group) will receive the active drug fluoxetine.

Study participants will be evaluated at baseline, post-exercise program and 6-months post-exercise program. While enrolled in the study, participants will be required to take part in a 12 week, 3 times per week exercise program. Evaluators and patients will be blind to the treatment administered. The trial is constructed with randomization to remove selection and allocation biases and to ensure greater validity in observed differences in the outcome measures. The Applied Health Research Centre (AHRC) in Toronto will act as the coordinating and analysis center.

02

Conditions studied

  • Stroke
  • Cerebrovascular Accident
  • Cerebral Infarction
  • Brain Infarction
  • Brain Ischemia
  • Cerebrovascular Disorders
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Vascular Diseases

Keywords

  • Stroke
  • Exercise
  • Fluoxetine
  • Randomized Control Trial
  • Rehabilitation
03

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. 25 years of age or older
  2. Days post stroke must be between 2 to 12 months when enrolled (i.e. day of consent)
  3. Patient-reported hemiparesis of the lower extremity

Exclusion criteria

Exclusion Criteria:

  1. Patients with subarachnoid hemorrhage
  2. Pre-morbid modified Rankin score > 2
  3. Substantial premorbid disability or pre-existing deficit or language comprehension deficit that could interfere with assessments
  4. Diagnosis of major depressive disorder/anxiety disorder requiring antidepressant use within 6 weeks of enrolment
  5. Taking neuroleptic drugs, benzodiazepines, monoamine oxidase inhibitors within 30 days of enrolment
  6. Unstable serious medical condition (e.g., terminal cancer, renal or liver failure, congestive heart failure)
  7. Resting blood pressure exceeding 180/100mmHg
  8. Requires more than a one person assist for transfer
  9. Planned surgery that would affect participation in the trial
  10. Participating in another formal lower limbs exercise program more than one day per week
  11. History of QT prolongation or concomitant use of clearly identified potential QT prolonging drugs, at the investigators discretion (e.g. amiodarone, bepridil, dysopyramide, dofetilide, flecainide, ibutilide, procainamide, propafenone, quinidine, sotalol, phenothiazines, pimozide, ziprasidone, TCAs, halofantrine, cisapride, and probucol)
  12. History of glaucoma
  13. Patients with a history of thrombocytopenia or clinically significant bleeding disorder or use of NSAID, ASA or other anticoagulants, at the investigators' discretion
  14. History of convulsive disorders
  15. Potential pregnancy (per screening algorithm)
  16. Patients with an ongoing history of illicit drug use and/or alcohol abuse
  17. Patient unwilling or unable to comply with trial requirements
  18. Patient unable to understand English or communicate with the study team with staff support or translation services
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Fluoxetine Hydrochloride

    Fluoxetine (Prozac) will be administered to this group. A ramp up period of 3-5 weeks will take place where the patient takes 10mg of Prozac per day. After that, the participant will take the regular dose of 20mg for the duration of the exercise intervention (12 weeks).

    Drug: Fluoxetine Hydrochloride · Behavioral: Exercise Program

  • Placebo comparator
    Placebo

    An over-encapsulated placebo, or "sugar pill" (so it appears identical to the trial drug) will be administered to this group. During the 3-5 week ramp up period for the experimental group, these participants will take a placebo identical to the 10mg Prozac capsule. After that, the participant will take a placebo identical to the 20mg Prozac capsule for the duration of the exercise intervention (12 weeks).

    Other: Placebo · Behavioral: Exercise Program

Interventions

  • DrugFluoxetine Hydrochloride

    Half of the participants will take fluoxetine for a period of 15-17 weeks (depending on ramp-up period).

    Also known as: Prozac

  • OtherPlacebo

    Half of the participants will take the a placebo for a period of 15-17 weeks (depending on ramp-up period).

    Also known as: "Sugar" Pill

  • BehavioralExercise Program

    All participants will take part in a 12-week exercise program. The program will run 3 times/week, 1 hour/class.

05

What researchers measure

Primary outcomes

  1. Fugl-Meyer Lower Extremity Score

    Fugl-Meyer Lower Extremity Assessment assesses motor and sensorimotor impairment in the lower extremities. Total score is between 0 and 34. Sub-scales include: proximal (0-18), knee/ankle (0-10) and coordination/speed (0-6). Higher scores indicate better performance. Sub-scale scores are summed to calculate total score.

    Time frame: Following completion of the 12-week exercise intervention

Secondary outcomes

  1. 6 Minute Walk Test / 10 Meter Walk Test

    Physical Measurement - Ambulatory Function

    Time frame: Following completion of the 12-week exercise intervention and 6-months post-exercise intervention

  2. Knee Strength

    Physical Measurement- Lower Limb Strength

    Time frame: Following completion of the 12-week exercise intervention and 6-months post-exercise intervention

  3. Berg Balance Assessment

    Physical Measurement - Balance Function

    Time frame: Following completion of the 12-week exercise intervention and 6-months post-exercise intervention

  4. Grip Strength

    Physical Measurement - Grip Strength

    Time frame: Following completion of the 12-week exercise intervention and 6-months post-exercise intervention

  5. Waist-to-Hip Ratio

    Physical Measurement - Health Measurement

    Time frame: Following completion of the 12-week exercise intervention and 6-months post-exercise intervention

  6. Body Mass Index

    Physical Measurement - Health Measurement

    Time frame: Following completion of the 12-week exercise intervention and 6-months post-exercise intervention

  7. Stroke Impact Scale

    Stroke-specific, self-report, health status measure. Assesses multiple domains on a 5-point Likert scale. Domains include: strength (4-20), hand function (5-25), activities of daily living/instrumental activities of daily living (10-50), mobility (9-45), communication (7-35), emotion (9-45), memory and thinking (7-35), and participation (8-40). An extra question asks that the patient rate on a scale from 0 - 100 how much they feel that he/she has recovered from his/her stroke. The 4 physical domains (strength, hand function, mobility and activities of daily living) can be summed together to create a single, physical dimension score (28-140) while all other domains should remain separate. Higher scores indicate better function.

    Time frame: Following completion of the 12-week exercise intervention and 6-months post-exercise intervention

  8. Fugl-Meyer Lower Extremity Score

    Impairment Measurement (see description above)

    Time frame: 6-months post-exercise intervention

  9. Fugl-Meyer Upper Extremity Score

    Fugl-Meyer Upper Extremity Assessment assesses motor and sensorimotor impairment in the upper extremities. There is no total score for this measure. Sub-scales include: upper extremity (0-36), wrist (0-10), hand (0-14), coordination/speed (0-6) (which can be combined to form a total motor function score out of 66), and sensation (0-4). Higher scores indicate better performance.

    Time frame: Following completion of the 12-week exercise intervention and 6-months post-exercise intervention

  10. Patient Health Questionnaire (PHQ)-9

    Depression Measurement

    Time frame: Following completion of the 12-week exercise intervention and 6-months post-exercise intervention

  11. Simple and Choice Reaction Time Test

    Cognitive Measurement

    Time frame: Following completion of the 12-week exercise intervention and 6-months post-exercise intervention

  12. Trail Making Test - A & B

    Cognitive Measurement

    Time frame: Following completion of the 12-week exercise intervention and 6-months post-exercise intervention

  13. Montreal Cognitive Assessment (including 5 word recall and clock test)

    Cognitive Measurement

    Time frame: Following completion of the 12-week exercise intervention and 6-months post-exercise intervention

  14. Fasting Blood Draws

    Biological Biomarker

    Time frame: Following completion of the 12-week exercise intervention and 6-months post-exercise intervention

06

Study locations

8 sites
  • University of Calgary
    Calgary, Alberta T2N 2T9, Canada
  • University of British Columbia & GF Strong Centre
    Vancouver, British Columbia V5Z 2G9, Canada
  • Riverview Health Centre
    Winnipeg, Manitoba R3L 2P4, Canada
  • Memorial University of Newfoundland
    St. John's, Newfoundland and Labrador A1A 1E5, Canada
  • Dalhousie University
    Halifax, Nova Scotia B3H 3J5, Canada
  • Parkwood Institute
    London, Ontario N6C 0A7, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Toronto Rehabilitation Institute - University Health Network
    Toronto, Ontario M5G 2A2, Canada
07

References and documents

Publications

  • Alexander LD, Black SE, Patterson KK, Gao F, Danells CJ, McIlroy WE. Association between gait asymmetry and brain lesion location in stroke patients. Stroke. 2009 Feb;40(2):537-44. doi: 10.1161/STROKEAHA.108.527374. Epub 2008 Dec 24. PubMed 19109546 ↗
  • AVERT Trial Collaboration group. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet. 2015 Jul 4;386(9988):46-55. doi: 10.1016/S0140-6736(15)60690-0. Epub 2015 Apr 16. Erratum In: Lancet. 2015 Jul 4;386(9988):30. doi: 10.1016/S0140-6736(15)61204-1. Lancet. 2017 May 13;389(10082):1884. doi: 10.1016/S0140-6736(17)31213-8. PubMed 25892679 ↗
  • Salbach NM, Wood-Dauphinee S, Desrosiers J, Eng JJ, Graham ID, Jaglal SB, Korner-Bitensky N, MacKay-Lyons M, Mayo NE, Richards CL, Teasell RW, Zwarenstein M, Bayley MT; Stroke Canada Optimization of Rehabilitation By Evidence - Implementation Trial (SCORE-IT) Team. Facilitated interprofessional implementation of a physical rehabilitation guideline for stroke in inpatient settings: process evaluation of a cluster randomized trial. Implement Sci. 2017 Aug 1;12(1):100. doi: 10.1186/s13012-017-0631-7. PubMed 28764752 ↗
  • Bensimon K, Herrmann N, Swardfager W, Yi H, Black SE, Gao FQ, Snaiderman A, Lanctot KL. Kynurenine and depressive symptoms in a poststroke population. Neuropsychiatr Dis Treat. 2014 Sep 22;10:1827-35. doi: 10.2147/NDT.S65740. eCollection 2014. PubMed 25285006 ↗
  • Berends HI, Nijlant J, van Putten M, Movig KL, IJzerman MJ. Single dose of fluoxetine increases muscle activation in chronic stroke patients. Clin Neuropharmacol. 2009 Jan-Feb;32(1):1-5. PubMed 19536922 ↗
  • Biernaskie J, Chernenko G, Corbett D. Efficacy of rehabilitative experience declines with time after focal ischemic brain injury. J Neurosci. 2004 Feb 4;24(5):1245-54. doi: 10.1523/JNEUROSCI.3834-03.2004. PubMed 14762143 ↗
  • Billinger SA, Arena R, Bernhardt J, Eng JJ, Franklin BA, Johnson CM, MacKay-Lyons M, Macko RF, Mead GE, Roth EJ, Shaughnessy M, Tang A; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Clinical Cardiology. Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Aug;45(8):2532-53. doi: 10.1161/STR.0000000000000022. Epub 2014 May 20. PubMed 24846875 ↗
  • Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature. 2002 Apr 11;416(6881):636-40. doi: 10.1038/416636a. PubMed 11948352 ↗
  • Breceda EY, Dromerick AW. Motor rehabilitation in stroke and traumatic brain injury: stimulating and intense. Curr Opin Neurol. 2013 Dec;26(6):595-601. doi: 10.1097/WCO.0000000000000024. PubMed 24141528 ↗
  • Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, Bejot Y, Deltour S, Jaillard A, Niclot P, Guillon B, Moulin T, Marque P, Pariente J, Arnaud C, Loubinoux I. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011 Feb;10(2):123-30. doi: 10.1016/S1474-4422(10)70314-8. Epub 2011 Jan 7. Erratum In: Lancet Neurol. 2011 Mar;10(3):205. PubMed 21216670 ↗
  • Cumberland Consensus Working Group; Cheeran B, Cohen L, Dobkin B, Ford G, Greenwood R, Howard D, Husain M, Macleod M, Nudo R, Rothwell J, Rudd A, Teo J, Ward N, Wolf S. The future of restorative neurosciences in stroke: driving the translational research pipeline from basic science to rehabilitation of people after stroke. Neurorehabil Neural Repair. 2009 Feb;23(2):97-107. doi: 10.1177/1545968308326636. PubMed 19189939 ↗
  • Dhami KS, Churchward MA, Baker GB, Todd KG. Fluoxetine and citalopram decrease microglial release of glutamate and D-serine to promote cortical neuronal viability following ischemic insult. Mol Cell Neurosci. 2013 Sep;56:365-74. doi: 10.1016/j.mcn.2013.07.006. Epub 2013 Jul 19. PubMed 23876875 ↗
  • Dromerick AW, Edwardson MA, Edwards DF, Giannetti ML, Barth J, Brady KP, Chan E, Tan MT, Tamboli I, Chia R, Orquiza M, Padilla RM, Cheema AK, Mapstone ME, Fiandaca MS, Federoff HJ, Newport EL. Critical periods after stroke study: translating animal stroke recovery experiments into a clinical trial. Front Hum Neurosci. 2015 Apr 29;9:231. doi: 10.3389/fnhum.2015.00231. eCollection 2015. PubMed 25972803 ↗
  • Espinera AR, Ogle ME, Gu X, Wei L. Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice. Neuroscience. 2013 Sep 5;247:1-11. doi: 10.1016/j.neuroscience.2013.04.011. Epub 2013 Apr 13. PubMed 23590907 ↗
  • Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, Roy D, Jovin TG, Willinsky RA, Sapkota BL, Dowlatshahi D, Frei DF, Kamal NR, Montanera WJ, Poppe AY, Ryckborst KJ, Silver FL, Shuaib A, Tampieri D, Williams D, Bang OY, Baxter BW, Burns PA, Choe H, Heo JH, Holmstedt CA, Jankowitz B, Kelly M, Linares G, Mandzia JL, Shankar J, Sohn SI, Swartz RH, Barber PA, Coutts SB, Smith EE, Morrish WF, Weill A, Subramaniam S, Mitha AP, Wong JH, Lowerison MW, Sajobi TT, Hill MD; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015 Mar 12;372(11):1019-30. doi: 10.1056/NEJMoa1414905. Epub 2015 Feb 11. PubMed 25671798 ↗
  • Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Wallin A, Dichgans M, Marler JR, Leblanc GG. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006 Sep;37(9):2220-41. doi: 10.1161/01.STR.0000237236.88823.47. Epub 2006 Aug 17. Erratum In: Stroke. 2007 Mar;38(3):1118. Wallin, Anders [added]. PubMed 16917086 ↗
  • Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-related quality of life among long-term survivors of stroke : results from the Auckland Stroke Study, 1991-1992. Stroke. 2000 Feb;31(2):440-7. doi: 10.1161/01.str.31.2.440. PubMed 10657420 ↗
  • Harris JE, Eng JJ, Miller WC, Dawson AS. A self-administered Graded Repetitive Arm Supplementary Program (GRASP) improves arm function during inpatient stroke rehabilitation: a multi-site randomized controlled trial. Stroke. 2009 Jun;40(6):2123-8. doi: 10.1161/STROKEAHA.108.544585. Epub 2009 Apr 9. PubMed 19359633 ↗
  • Hsieh YW, Wang CH, Sheu CF, Hsueh IP, Hsieh CL. Estimating the minimal clinically important difference of the Stroke Rehabilitation Assessment of Movement measure. Neurorehabil Neural Repair. 2008 Nov-Dec;22(6):723-7. doi: 10.1177/1545968308316385. Epub 2008 Sep 5. PubMed 18776067 ↗
  • Hsueh IP, Hsu MJ, Sheu CF, Lee S, Hsieh CL, Lin JH. Psychometric comparisons of 2 versions of the Fugl-Meyer Motor Scale and 2 versions of the Stroke Rehabilitation Assessment of Movement. Neurorehabil Neural Repair. 2008 Nov-Dec;22(6):737-44. doi: 10.1177/1545968308315999. Epub 2008 Jul 21. PubMed 18645189 ↗
  • Iadecola C, Anrather J. Stroke research at a crossroad: asking the brain for directions. Nat Neurosci. 2011 Oct 26;14(11):1363-8. doi: 10.1038/nn.2953. PubMed 22030546 ↗
  • Jorgensen HS, Nakayama H, Raaschou HO, Vive-Larsen J, Stoier M, Olsen TS. Outcome and time course of recovery in stroke. Part I: Outcome. The Copenhagen Stroke Study. Arch Phys Med Rehabil. 1995 May;76(5):399-405. doi: 10.1016/s0003-9993(95)80567-2. PubMed 7741608 ↗
  • Kobayashi K, Ikeda Y, Sakai A, Yamasaki N, Haneda E, Miyakawa T, Suzuki H. Reversal of hippocampal neuronal maturation by serotonergic antidepressants. Proc Natl Acad Sci U S A. 2010 May 4;107(18):8434-9. doi: 10.1073/pnas.0912690107. Epub 2010 Apr 19. PubMed 20404165 ↗
  • Krakauer JW, Carmichael ST, Corbett D, Wittenberg GF. Getting neurorehabilitation right: what can be learned from animal models? Neurorehabil Neural Repair. 2012 Oct;26(8):923-31. doi: 10.1177/1545968312440745. Epub 2012 Mar 30. PubMed 22466792 ↗
  • Kwah LK, Harvey LA, Diong J, Herbert RD. Models containing age and NIHSS predict recovery of ambulation and upper limb function six months after stroke: an observational study. J Physiother. 2013 Sep;59(3):189-97. doi: 10.1016/S1836-9553(13)70183-8. Erratum In: J Physiother. 2013 Dec;59(4):218. PubMed 23896334 ↗
  • Langdon KD, Corbett D. Improved working memory following novel combinations of physical and cognitive activity. Neurorehabil Neural Repair. 2012 Jun;26(5):523-32. doi: 10.1177/1545968311425919. Epub 2011 Dec 9. PubMed 22157145 ↗
  • Levine B, Schweizer TA, O'Connor C, Turner G, Gillingham S, Stuss DT, Manly T, Robertson IH. Rehabilitation of executive functioning in patients with frontal lobe brain damage with goal management training. Front Hum Neurosci. 2011 Feb 17;5:9. doi: 10.3389/fnhum.2011.00009. eCollection 2011. PubMed 21369362 ↗
  • Lynch E, Hillier S, Cadilhac D. When should physical rehabilitation commence after stroke: a systematic review. Int J Stroke. 2014 Jun;9(4):468-78. doi: 10.1111/ijs.12262. Epub 2014 Mar 18. PubMed 24636633 ↗
  • Mackay-Lyons M, McDonald A, Matheson J, Eskes G, Klus MA. Dual effects of body-weight supported treadmill training on cardiovascular fitness and walking ability early after stroke: a randomized controlled trial. Neurorehabil Neural Repair. 2013 Sep;27(7):644-53. doi: 10.1177/1545968313484809. Epub 2013 Apr 18. PubMed 23599221 ↗
  • Mansfield A, Wong JS, Bryce J, Brunton K, Inness EL, Knorr S, Jones S, Taati B, McIlroy WE. Use of Accelerometer-Based Feedback of Walking Activity for Appraising Progress With Walking-Related Goals in Inpatient Stroke Rehabilitation: A Randomized Controlled Trial. Neurorehabil Neural Repair. 2015 Oct;29(9):847-57. doi: 10.1177/1545968314567968. Epub 2015 Jan 20. PubMed 25605632 ↗
  • Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O'Leary OF, Castren E, Maffei L. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science. 2008 Apr 18;320(5874):385-8. doi: 10.1126/science.1150516. PubMed 18420937 ↗
  • McEwen D, Taillon-Hobson A, Bilodeau M, Sveistrup H, Finestone H. Virtual reality exercise improves mobility after stroke: an inpatient randomized controlled trial. Stroke. 2014 Jun;45(6):1853-5. doi: 10.1161/STROKEAHA.114.005362. Epub 2014 Apr 24. PubMed 24763929 ↗
  • McIntyre A, Richardson M, Janzen S, Hussein N, Teasell R. The evolution of stroke rehabilitation randomized controlled trials. Int J Stroke. 2014 Aug;9(6):789-92. doi: 10.1111/ijs.12272. Epub 2014 Mar 13. PubMed 24621406 ↗
  • Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci. 2009 Dec;10(12):861-72. doi: 10.1038/nrn2735. Epub 2009 Nov 4. PubMed 19888284 ↗
  • Nadeau SE, Wu SS, Dobkin BH, Azen SP, Rose DK, Tilson JK, Cen SY, Duncan PW; LEAPS Investigative Team. Effects of task-specific and impairment-based training compared with usual care on functional walking ability after inpatient stroke rehabilitation: LEAPS Trial. Neurorehabil Neural Repair. 2013 May;27(4):370-80. doi: 10.1177/1545968313481284. Epub 2013 Mar 15. PubMed 23504552 ↗
  • Pizzorusso T, Medini P, Berardi N, Chierzi S, Fawcett JW, Maffei L. Reactivation of ocular dominance plasticity in the adult visual cortex. Science. 2002 Nov 8;298(5596):1248-51. doi: 10.1126/science.1072699. PubMed 12424383 ↗
  • Ploughman M, Granter-Button S, Chernenko G, Tucker BA, Mearow KM, Corbett D. Endurance exercise regimens induce differential effects on brain-derived neurotrophic factor, synapsin-I and insulin-like growth factor I after focal ischemia. Neuroscience. 2005;136(4):991-1001. doi: 10.1016/j.neuroscience.2005.08.037. Epub 2005 Oct 3. PubMed 16203102 ↗
  • Ploughman M, Windle V, MacLellan CL, White N, Dore JJ, Corbett D. Brain-derived neurotrophic factor contributes to recovery of skilled reaching after focal ischemia in rats. Stroke. 2009 Apr;40(4):1490-5. doi: 10.1161/STROKEAHA.108.531806. Epub 2009 Jan 22. PubMed 19164786 ↗
  • Pollock A, St George B, Fenton M, Firkins L. Top 10 research priorities relating to life after stroke--consensus from stroke survivors, caregivers, and health professionals. Int J Stroke. 2014 Apr;9(3):313-20. doi: 10.1111/j.1747-4949.2012.00942.x. Epub 2012 Dec 11. PubMed 23227818 ↗
  • Portelli R, Lowe D, Irwin P, Pearson M, Rudd AG; Intercollegiate Stroke Working Party. Institutionalization after stroke. Clin Rehabil. 2005 Jan;19(1):97-108. doi: 10.1191/0269215505cr822oa. PubMed 15704514 ↗
  • Savitz SI, Cramer SC, Wechsler L; STEPS 3 Consortium. Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials. Stroke. 2014 Feb;45(2):634-9. doi: 10.1161/STROKEAHA.113.003379. Epub 2013 Dec 24. No abstract available. PubMed 24368562 ↗
  • Scali M, Begenisic T, Mainardi M, Milanese M, Bonifacino T, Bonanno G, Sale A, Maffei L. Fluoxetine treatment promotes functional recovery in a rat model of cervical spinal cord injury. Sci Rep. 2013;3:2217. doi: 10.1038/srep02217. PubMed 23860568 ↗
  • Soleman S, Yip PK, Duricki DA, Moon LD. Delayed treatment with chondroitinase ABC promotes sensorimotor recovery and plasticity after stroke in aged rats. Brain. 2012 Apr;135(Pt 4):1210-23. doi: 10.1093/brain/aws027. Epub 2012 Mar 6. PubMed 22396394 ↗
  • Stinear CM, Byblow WD. Predicting and accelerating motor recovery after stroke. Curr Opin Neurol. 2014 Dec;27(6):624-30. doi: 10.1097/WCO.0000000000000153. PubMed 25364953 ↗
  • Van Breukelen GJ. ANCOVA versus change from baseline: more power in randomized studies, more bias in nonrandomized studies [corrected]. J Clin Epidemiol. 2006 Sep;59(9):920-5. doi: 10.1016/j.jclinepi.2006.02.007. Epub 2006 Jun 23. Erratum In: J Clin Epidemiol. 2006 Dec;59(12):1334. PubMed 16895814 ↗
  • Vickers AJ. Analysis of variance is easily misapplied in the analysis of randomized trials: a critique and discussion of alternative statistical approaches. Psychosom Med. 2005 Jul-Aug;67(4):652-5. doi: 10.1097/01.psy.0000172624.52957.a8. PubMed 16046383 ↗
  • Wade DT, Skilbeck CE, Wood VA, Langton Hewer R. Long-term survival after stroke. Age Ageing. 1984 Mar;13(2):76-82. doi: 10.1093/ageing/13.2.76. PubMed 6731168 ↗
  • Wahl AS, Omlor W, Rubio JC, Chen JL, Zheng H, Schroter A, Gullo M, Weinmann O, Kobayashi K, Helmchen F, Ommer B, Schwab ME. Neuronal repair. Asynchronous therapy restores motor control by rewiring of the rat corticospinal tract after stroke. Science. 2014 Jun 13;344(6189):1250-5. doi: 10.1126/science.1253050. PubMed 24926013 ↗
  • Wang CH, Hsieh CL, Dai MH, Chen CH, Lai YF. Inter-rater reliability and validity of the stroke rehabilitation assessment of movement (stream) instrument. J Rehabil Med. 2002 Jan;34(1):20-4. doi: 10.1080/165019702317242668. PubMed 11900258 ↗
  • Wang D, Fawcett J. The perineuronal net and the control of CNS plasticity. Cell Tissue Res. 2012 Jul;349(1):147-60. doi: 10.1007/s00441-012-1375-y. Epub 2012 Mar 23. PubMed 22437874 ↗
  • Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair. 2008 May-Jun;22(3):311-4. doi: 10.1177/1545968307312173. Epub 2008 Jan 24. PubMed 18219053 ↗

Individual participant data

Plan to share: Undecided — Unused blood samples will be processed and centrally stored in cryovials in a minus 80 degrees freezer for future analyses under the supervision of Study Investigator, Dr. Sandra Black (Sunnybrook, M6 West, 2075 Bayview Avenue, Toronto). The intent is to make the stored frozen cryovials available to all Heart and Stroke Foundation Canadian Partnership of Stroke Recovery (CPSR) investigators to apply for access, but it is currently undecided if other researchers will be allowed to apply for access to the samples. Access will be controlled by a Subcommittee of CPSR Investigators who will review and approve requests and oversee access to the biobank. Stored cryovials will remain at Sunnybrook under the supervision of Dr. Sandra Black for a period of up to 10 years.

08

Registry details

Key details

Study ID
NCT03448159
Lead sponsor
University Health Network, Toronto
Collaborators
University of British Columbia, Sunnybrook Health Sciences Centre, University of Calgary, Dalhousie University, Parkwood Hospital, London, Ontario, Riverview Health Centre Foundation, Memorial University of Newfoundland, Applied Health Research Centre, Brain Canada, Heart and Stroke Foundation Canadian Partnership for Stroke Recovery
Responsible party
Sponsor
First posted
Feb 27, 2018
Start date
Jan 1, 2019
Primary completion
Sep 30, 2022
Completion
Sep 30, 2022
Last update
Nov 4, 2022

Study contacts

Mark Bayley, MD
principal investigator · University Health Network, Toronto
Courtney Pollock, PhD
principal investigator · University of British Columbia & GF Strong Rehab Centre
Bradley MacIntosh, PhD
principal investigator · Sunnybrook Health Sciences Centre
Sean Dukelow, MD
principal investigator · University of Calgary
Sepideh Pooyania, MD
principal investigator · Riverview Health Centre
Michelle Ploughman, PhD
principal investigator · Memorial University of Newfoundland
Marilyn Mackay-Lyons, PhD
principal investigator · Dalhousie University
Robert Teasell, MD
principal investigator · Parkwood Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion